ABSTRACT
PsoP27 is an antigen expressed in psoriatic lesions. It plays an inflammatory role in psoriasis. This study objective was to characterize antibodies (Abs) against PsoP27 in patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Levels of Abs against native and citrullinated PsoP27 in PsA and RA patients' synovial fluid (SF) and sera were determined by ELISA. SF of osteoarthritis (OA) patients and sera of healthy donors were used as controls. Levels of Abs against PsoP27 were correlated with disease activity scores. Abs against native and citrullinated PsoP27 levels in SF of PsA (n = 48; 0.38 ± 0.03 and 0.44 ± 0.04, respectively) and RA (n = 22; 0.57 ± 0.1 and 0.62 ± 0.09, respectively) were significantly higher than in OA patients (n = 23; 0.14 ± 0.01 and 0.15 ± 0.01, respectively) (p < .0001). For both Abs, there were no significant differences between their level in PsA and RA patients. There was no difference in the level of Abs against citrullinated PsoP27 in SF of seronegative versus seropositive RA patients. Levels of Abs against both native and citrullinated PsoP27 in the SF and level of systemic C-reactive protein in PsA correlated positively, while in RA there were no significant correlations with disease activity scores. No differences in level of Abs against PsoP27 were found in the sera of all three study groups. Abs against native and citrullinated PsoP27 are present in PsA and RA SF but not in those of OA patients, suggesting a potential role of those Abs in inflammatory joint diseases.
Subject(s)
Arthritis, Psoriatic , Arthritis, Rheumatoid , Autoantibodies , Synovial Fluid , Humans , Arthritis, Psoriatic/immunology , Arthritis, Psoriatic/blood , Arthritis, Psoriatic/metabolism , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/blood , Synovial Fluid/immunology , Synovial Fluid/metabolism , Autoantibodies/blood , Autoantibodies/immunology , Male , Middle Aged , Female , Adult , Aged , Case-Control Studies , Osteoarthritis/immunology , Osteoarthritis/blood , Enzyme-Linked Immunosorbent AssayABSTRACT
OBJECTIVE: While biologics have been used for the patients with psoriatic arthritis, there remains to be unknown concerning long-term retention rates. This study aims to present real-world data about long-term retention rates of biologics for the patients with psoriatic arthritis, and to undertake an analysis of the contributing factors. METHODS: We examined retention rates and the reasons for discontinuation for biologics (adalimumab, certolizumab pegol, secukinumab, and ixekizumab) in 146 prescriptions (of which, 109 prescriptions were as naive) at our hospital since March 2010. RESULTS: Throughout the entire course of the study, the 10-year retention rates were approximately 70% for adalimumab, 50% for ixekizumab, and 40% for secukinumab. When evaluating retention rates in the biologic-naïve subgroups, the 10-year retention rates were all approximately 70%. Regarding certolizumab pegol, the 3-year retention rate was approximately 75%. For adalimumab, a higher degree of arthritis at the initiation of treatment was found to correlate with an increased likelihood of secondary inefficacy. The main reason for discontinuation was secondary inefficacy, except for ixekizumab. CONCLUSIONS: Each biologic exhibited a favourable long-term retention rate. The main reason for discontinuation was secondary inefficacy. Regarding adalimumab, secondary inefficacy was linked to the extent of arthritis upon treatment initiation.
Subject(s)
Antibodies, Monoclonal, Humanized , Antirheumatic Agents , Arthritis, Psoriatic , Interleukin-17 , Humans , Arthritis, Psoriatic/drug therapy , Arthritis, Psoriatic/immunology , Male , Female , Middle Aged , Interleukin-17/antagonists & inhibitors , Interleukin-17/immunology , Antibodies, Monoclonal, Humanized/therapeutic use , Adult , Antirheumatic Agents/therapeutic use , Adalimumab/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Certolizumab Pegol/therapeutic use , Aged , Biological Products/therapeutic use , Treatment OutcomeABSTRACT
In recent years, research has intensified in exploring the genetic basis of psoriasis (PsO) and psoriatic arthritis (PsA). Genome-wide association studies (GWASs), including tools like ImmunoChip, have significantly deepened our understanding of disease mechanisms by pinpointing risk-associated genetic loci. These efforts have elucidated biological pathways involved in PsO pathogenesis, particularly those related to the innate immune system, antigen presentation, and adaptive immune responses. Specific genetic loci, such as TRAF3IP2, REL, and FBXL19, have been identified as having a significant impact on disease development. Interestingly, different genetic variants at the same locus can predispose individuals to either PsO or PsA (e.g., IL23R and deletion of LCE3B and LCE3C), with some variants being uniquely linked to PsA (like HLA B27 on chromosome 6). This article aims to summarize known and new data on the genetics of PsO and PsA, their associated genes, and the involvement of the HLA system and cytokines.
Subject(s)
Arthritis, Psoriatic , Cytokines , Genetic Predisposition to Disease , Genome-Wide Association Study , HLA Antigens , Psoriasis , Humans , Arthritis, Psoriatic/genetics , Arthritis, Psoriatic/immunology , Psoriasis/genetics , Psoriasis/immunology , HLA Antigens/geneticsABSTRACT
We aim to systemically review the genomics, transcriptomics, epigenetics, proteomics, metabonomics and microbiota of psoriatic arthritis and psoriasis, illustrating the differences of these two diseases, broadening our understanding of the pathogenesis of them and providing important clues for valuable biomarkers of earlier diagnosis and treatments. To our knowledge, this is the first study that combine all omics studies from genomics to microbiota and may serve as a reference for future studies to identify the key underlying pathways in psoriatic arthritis.
Subject(s)
Arthritis, Psoriatic , Genomics , Metabolomics , Proteomics , Psoriasis , Humans , Arthritis, Psoriatic/diagnosis , Arthritis, Psoriatic/immunology , Psoriasis/diagnosis , Psoriasis/immunology , Genomics/methods , Microbiota/immunology , Biomarkers/metabolism , Epigenesis, Genetic , Transcriptome , MultiomicsABSTRACT
Objectives: Programmed cell death protein-1 (PD-1) maintains peripheral immune tolerance by preventing T cell continuous activation. Aiming to understand the extent of PD-1 expression in inflammatory arthritis beyond its involvement with T cells, we assess its presence on various circulating single cells. Methods: Mass cytometry analysis of patients with active seropositive/seronegative rheumatoid (RA; n=9/8) and psoriatic (PsA; n=9) arthritis versus healthy controls (HC; n=13), re-evaluating patients after 3 months of anti-rheumatic treatment. Results: PD-1 was expressed in all leukocyte subpopulations, with the highest PD-1+ cell frequencies in eosinophils (59-73%) and T cells (50-60%), and the lowest in natural-killer cells (1-3%). PD-1+ cell frequencies and PD-1 median expression were comparable between patient subgroups and HC, in the majority of cell subsets. Exceptions included increases in certain T cell/B cell subsets of seropositive RA and specific monocyte subsets and dendritic cells of PsA; an expanded PD-1+CD4+CD45RA+CD27+CD28+ T subset, denoting exhausted T cells, was common across patient subgroups. Strikingly, significant inverse correlations between individual biomarkers of systemic inflammation (ESR and/or serum CRP) and PD-1+ cell frequencies and/or median expression were evident in several innate and adaptive immunity cell subsets of RA and PsA patients. Furthermore, all inverse correlations noted in individuals with active arthritis were no longer discernible in those who attained remission/low disease activity post-treatment. Conclusion: PD-1 expression may be insufficient, relative to the magnitude of the concomitant systemic inflammatory response on distinct leukocyte subsets, varying between RA and PsA. Our results point to the potential therapeutic benefits of pharmacological PD-1 activation, to rebalance the autoimmune response and reduce inflammation.
Subject(s)
Arthritis, Psoriatic , Arthritis, Rheumatoid , Programmed Cell Death 1 Receptor , Proteomics , Single-Cell Analysis , Humans , Programmed Cell Death 1 Receptor/metabolism , Male , Female , Middle Aged , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/blood , Arthritis, Psoriatic/immunology , Proteomics/methods , Aged , Adult , Autoimmunity , BiomarkersABSTRACT
Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases. We propose studies to advance IL-23 biology and unravel differences in response to anti-IL-23 therapy. Experimental evidence generated from these investigations could establish a novel molecular ontology centered around IL-23-driven diseases, improve upon current approaches to treating IMIDs with IL-23 inhibition, and ultimately facilitate optimal identification of patients and, thereby, outcomes.
Subject(s)
Interleukin-23 , Animals , Humans , Arthritis, Psoriatic/immunology , Arthritis, Psoriatic/drug therapy , Inflammatory Bowel Diseases/immunology , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/therapy , Interleukin-23/antagonists & inhibitors , Interleukin-23/immunology , Interleukin-23/metabolism , Psoriasis/immunology , Psoriasis/drug therapy , Signal TransductionABSTRACT
Psoriatic arthritis (PsA) is part of the psoriatic disease spectrum and is characterized by a chronic inflammatory process that affects entheses, tendons and joints. Cytokines produced by immune and non-immune cells play a central role in the pathogenesis of PsA by orchestrating key aspects of the inflammatory response. Pro-inflammatory cytokines such as TNF, IL-23 and IL-17 have been shown to regulate the initiation and progression of PsA, ultimately leading to the destruction of the architecture of the local tissues such as soft tissue, cartilage and bone. The important role of cytokines in PsA has been underscored by the clinical success of antibodies that neutralize their function. In addition to biologic agents targeting individual pro-inflammatory cytokines, signaling inhibitors that block multiple cytokines simultaneously such as JAK inhibitors have been approved for PsA therapy. In this review, we will focus on our current understanding of the role of cytokines in the disease process of PsA and discuss potential new treatment options based on modulation of cytokine function.
Subject(s)
Arthritis, Psoriatic , Cytokines , Arthritis, Psoriatic/drug therapy , Arthritis, Psoriatic/immunology , Humans , Cytokines/immunology , Animals , Interleukin-17/antagonists & inhibitors , Interleukin-17/immunology , Interleukin-23/immunology , Interleukin-23/antagonists & inhibitors , Signal Transduction , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/immunology , Janus Kinase Inhibitors/therapeutic useABSTRACT
The purpose of this research was to characterize the microbiota of patients with psoriatic arthritis (PsA) and to compare the relationship between the microbiota and peripheral lymphocyte subsets and cytokines. We collected stool samples from 13 PsA patients and 26 sex- and age-matched healthy controls (HCs) and researched the gut microbiota by sequencing the V3-V4 variable region of the bacterial 16S rRNA gene with the Illumina Miseq PE300 system. Flow cytometry was used to assess the peripheral lymphocyte subsets in these participants. Record measures of disease activity such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Alpha and beta diversity were assessed using results from QIIME2. Panel demonstrated the average relative abundance of the different genera in PsA and HCs. Correlation between clinical parameters and the relative abundance of the genus in samples was assessed by the Pearson correlation analysis using R (version 4.0.1). Compared with HC, the abundance of gut microbiota (Chao 1 and ACE) decreased in patients with PsA, and the diversity of bacteria (Shannon and Simpson indices) also decreased in PsA (Fig. 1a). ß Diversity analysis indicated differences in microbial communities between PsA and HC (Fig. 1b, r = 0.039, p = 0.264, ANOSIM). Furthermore, 18 bacterial groups were significantly different at the genus level in PsA compared to HCs (p < 0.05) (Fig. 2).In the phylum and genus, lymphocyte subsets and cytokines are associated with the microbiota. The gut microbiota of patients with PsA differs from HC, which was closely related to lymphocyte subsets.
Subject(s)
Arthritis, Psoriatic , Cytokines , Dysbiosis , Gastrointestinal Microbiome , Lymphocyte Subsets , Humans , Arthritis, Psoriatic/immunology , Arthritis, Psoriatic/microbiology , Gastrointestinal Microbiome/immunology , Cytokines/metabolism , Male , Female , Adult , Middle Aged , Dysbiosis/microbiology , Dysbiosis/immunology , Lymphocyte Subsets/immunology , RNA, Ribosomal, 16S/geneticsABSTRACT
Psoriatic arthritis (PsA) is a complex inflammatory disease that challenges diagnosis and complicates the rational selection of effective therapies. Although T cells are considered active effectors in psoriasis and PsA, the role of CD8+ T cells in pathogenesis is not well understood. We selected the humanized mouse model NSG-SGM3 transgenic strain to examine psoriasis and PsA endotypes. Injection of PBMCs and sera from patients with psoriasis and PsA generated parallel skin and joint phenotypes in the recipient mouse. The transfer of human circulating memory T cells was followed by migration and accumulation in the skin and synovia of these immunodeficient mice. Unexpectedly, immunoglobulins were required for recapitulation of the clinical phenotype of psoriasiform lesions and PsA domains (dactylitis, enthesitis, bone erosion). Human CD8+ T cells expressing T-bet, IL-32 and CXCL14 were detected by spatial transcriptomics in murine synovia and by immunofluorescence in the human PsA synovia. Importantly, depletion of human CD8+ T cells prevented skin and synovial inflammation in mice humanized with PsA peripheral blood cells. The humanized model of psoriasis and PsA represents a valid platform for accelerating the understanding of disease pathogenesis, improving the design of personalized therapies, and revealing psoriatic disease targets.
Subject(s)
Arthritis, Psoriatic , CD8-Positive T-Lymphocytes , Disease Models, Animal , Animals , Arthritis, Psoriatic/immunology , Arthritis, Psoriatic/pathology , Humans , Mice , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Mice, Transgenic , Skin/pathology , Skin/immunology , Female , Male , Phenotype , Psoriasis/immunology , Psoriasis/pathologyABSTRACT
AIM: This study aimed to construct prognostic mathematical models utilizing multifactorial regression analysis to assess the risk of developing drug-induced neutralizing antibodies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with tumor necrosis factor alpha blockers.
Subject(s)
Antibodies, Neutralizing , Arthritis, Psoriatic , Arthritis, Rheumatoid , Spondylitis, Ankylosing , Tumor Necrosis Factor-alpha , Humans , Spondylitis, Ankylosing/drug therapy , Spondylitis, Ankylosing/immunology , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/immunology , Arthritis, Psoriatic/drug therapy , Arthritis, Psoriatic/immunology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/immunology , Prognosis , Male , Female , Middle Aged , Adult , Antirheumatic Agents/therapeutic use , Models, TheoreticalABSTRACT
Objectives: IL26 levels are elevated in the blood and synovial fluid of patients with inflammatory arthritis. IL26 can be produced by Th17 cells and locally within joints by tissue-resident cells. IL26 induces osteoblast mineralization in vitro. As osteoproliferation and Th17 cells are important factors in the pathogenesis of axial spondyloarthritis (axSpA), we aimed to clarify the cellular sources of IL26 in spondyloarthritis. Methods: Serum, peripheral blood mononuclear cells (n = 15-35) and synovial tissue (n = 3-9) of adult patients with axSpA, psoriatic arthritis (PsA) and rheumatoid arthritis (RA) and healthy controls (HCs, n = 5) were evaluated by ELISA, flow cytometry including PrimeFlow assay, immunohistochemistry and immunofluorescence and quantitative PCR. Results: Synovial tissue of axSpA patients shows significantly more IL26-positive cells than that of HCs (p < 0.01), but numbers are also elevated in PsA and RA patients. Immunofluorescence shows co-localization of IL26 with CD68, but not with CD3, SMA, CD163, cadherin-11, or CD90. IL26 is elevated in the serum of RA and PsA (but not axSpA) patients compared with HCs (p < 0.001 and p < 0.01). However, peripheral blood CD4+ T cells from axSpA and PsA patients show higher positivity for IL26 in the PrimeFlow assay compared with HCs. CD4+ memory T cells from axSpA patients produce more IL26 under Th17-favoring conditions (IL-1ß and IL-23) than cells from PsA and RA patients or HCs. Conclusion: IL26 production is increased in the synovial tissue of SpA and can be localized to CD68+ macrophage-like synoviocytes, whereas circulating IL26+ Th17 cells are only modestly enriched. Considering the osteoproliferative properties of IL26, this offers new therapeutic options independent of Th17 pathways.
Subject(s)
Antigens, CD , Arthritis, Psoriatic , Interleukins , Synoviocytes , Humans , Arthritis, Psoriatic/immunology , Arthritis, Psoriatic/metabolism , Synoviocytes/metabolism , Synoviocytes/immunology , Synoviocytes/pathology , Male , Adult , Female , Antigens, CD/metabolism , Interleukins/metabolism , Interleukins/blood , Middle Aged , Antigens, Differentiation, Myelomonocytic/metabolism , Axial Spondyloarthritis/immunology , Th17 Cells/immunology , Th17 Cells/metabolism , Synovial Membrane/immunology , Synovial Membrane/metabolism , Synovial Membrane/pathology , Joints/pathology , Joints/immunology , Joints/metabolism , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/metabolism , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/pathologyABSTRACT
Restoring peripheral immune tolerance is crucial for addressing autoimmune diseases. An ancient mechanism in maintaining the balance between inflammation and tolerance is the ratio of extracellular ATP (exATP) and adenosine. Our previous research demonstrated the effectiveness of small spleen peptides (SSPs) in inhibiting psoriatic arthritis progression, even in the presence of the pro-inflammatory cytokine TNFα, by transforming dendritic cells (DCs) into tolerogenic cells and fostering regulatory Foxp3+ Treg cells. Here, we identified thymosins as the primary constituents of SSPs, but recombinant thymosin peptides were less efficient in inhibiting arthritis than SSPs. Since Tß4 is an ecto-ATPase-binding protein, we hypothesized that SSPs regulate exATP profiles. Real-time investigation of exATP levels in DCs revealed that tolerogenic stimulation led to robust de novo exATP synthesis followed by significant degradation, while immunogenic stimulation resulted in a less pronounced increase in exATP and less effective degradation. These contrasting exATP profiles were crucial in determining whether DCs entered an inflammatory or tolerogenic state, highlighting the significance of SSPs as natural regulators of peripheral immunological tolerance, with potential therapeutic benefits for autoimmune diseases. Finally, we demonstrated that the tolerogenic phenotype of SSPs is mainly influenced by adenosine receptors, and in vivo administration of SSPs inhibits psoriatic skin inflammation.
Subject(s)
Adenosine Triphosphate , Cell Differentiation , Dendritic Cells , Spleen , Dendritic Cells/metabolism , Dendritic Cells/drug effects , Dendritic Cells/immunology , Adenosine Triphosphate/metabolism , Adenosine Triphosphate/pharmacology , Animals , Cell Differentiation/drug effects , Spleen/cytology , Spleen/metabolism , Spleen/drug effects , Spleen/immunology , Mice , Thymosin/pharmacology , Thymosin/metabolism , Peptides/pharmacology , Arthritis, Psoriatic/drug therapy , Arthritis, Psoriatic/metabolism , Arthritis, Psoriatic/immunology , Humans , Mice, Inbred C57BL , Immune Tolerance/drug effectsABSTRACT
Biologics and Janus kinase (JAK) inhibitors are immunomodulating and immunosuppressing medications utilized to treat atopic dermatitis (AD), psoriasis (PSO), psoriatic arthritis (PsA), and alopecia areata (AA). Special recommendations must be considered when prescribing vaccinations in this population, as the pneumococcal and herpes zoster vaccine are recommended to patients ≥ 19-years-old (rather than ≥ 65-years-old and ≥ 50-years-old as in the general population, respectively), along with a yearly influenza and up to date COVID-19 vaccination. Additionally, TNF-α and JAK-inhibitors may increase the risk of latent Hepatitis B virus (HBV) reactivation among high-risk patients. Prior to prescribing these medications, a quantitative HepB Surface Antibody (HepB SA) test is performed to determine immunity. This study utilized the SlicerDicer function on EPIC Medical Records to search for any patient ≥ 19-years-old prescribed a biologic or JAK inhibitor for AD, PSO, PsA, or AA between 10/2003 and 10/2023 at a large tertiary institution. Vaccination rates among patients on biologics and JAK inhibitors were low, with rates being significantly lower in patients 19-64 years-old, compared to those ≥ 65 years-old for most disease states (p < 0.01). Among AD, PSO/PsA, and AA patients, on average, 9.39% were vaccinated for influenza, 6.76% for herpes zoster, 16.56% for pneumococcal pneumonia, and 63.98% for COVID-19. Only 3.16% of patients were adequately vaccinated for HepB after an abnormal HepB SA test. Here, extremely low rates of vaccination among patients on biologics and JAK inhibitors at our institution were highlighted, emphasizing the imperative need for ensuring vaccination in this group.
Subject(s)
Alopecia Areata , Arthritis, Psoriatic , Biological Products , Dermatitis, Atopic , Vaccination , Humans , Middle Aged , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/immunology , Dermatitis, Atopic/epidemiology , Male , Adult , Female , Alopecia Areata/immunology , Alopecia Areata/drug therapy , Alopecia Areata/epidemiology , Biological Products/therapeutic use , Biological Products/adverse effects , Aged , Young Adult , Arthritis, Psoriatic/drug therapy , Arthritis, Psoriatic/immunology , Vaccination/statistics & numerical data , Janus Kinase Inhibitors/therapeutic use , Psoriasis/drug therapy , Psoriasis/immunology , COVID-19/prevention & control , COVID-19/epidemiology , COVID-19/immunology , Retrospective Studies , SARS-CoV-2/immunologyABSTRACT
BACKGROUND: HLA-B27 is associated with spondyloarthritis, a group of diseases that includes psoriatic arthritis. OBJECTIVES: To describe the HLA-B27 frequency in a group of Brazilian patients with psoriatic arthritis and correlate its presence or absence with their clinical manifestations. METHODS: Cross-sectional study with 44 psoriatic arthritis patients of a Rheumatology clinic. Demographic and social data were recorded, as were skin and joints clinical examination. HLA-B27 was tested. All data were processed descriptively and comparatively by appropriate software. Parametric and non parametric tests were used with 5% statistical significance. RESULTS: HLA-B27 was negative in 32 of the 44 patients (72,7%). Most of them were male, Caucasian, living in Rio de Janeiro, with plaque type psoriasis and average age of 52,9 years. There was statistical significant correlation between positive HLA-B27 and male gender (p=0,004). Negative HLA-B27 had a tendency to correlate with hands and wrists arthritis (p=0,07). There was an inverse significant correlation between HLA values and Schöber's test (p=0,02). CONCLUSION: Although HLA-B27 is negative in most of patients, it is significantly associated to male gender and inversely correlated with Schöber's test.
FUNDAMENTOS: O HLA-B27 está associado às espondiloartrites, grupo de doenças que engloba, entre outras, a artrite psoriásica. OBJETIVOS: Descrever a freqüência de HLA-B27 em uma amostra de pacientes brasileiros com artrite psoriásica e correlacionar sua presença ou ausência com as manifestações clínicas dos mesmos. MÉTODOS: Estudo transversal avaliando 44 pacientes com artrite psoriásica de um ambulatório de Reumatologia. A avaliação consistia em registro de informações demográficas e sociais, exame clínico da pele e das articulações e pesquisa de HLA-B27. Os dados gerados foram tratados por meio de estatística descritiva e comparativa em Software apropriado. Foram utilizados testes paramétricos e não-paramétricos com significância estatística de 5%. RESULTADOS: O HLA-B27 resultou negativo em 32 dos 44 pacientes estudados (72,7%). A maioria dos pacientes era do sexo masculino, da raça branca, procedente do Rio de Janeiro, portador de psoríase em placas e com idade média de 52,9 anos. Houve associação estatisticamente significativa entre o HLA-B27 positivo e o sexo masculino (p=0,004). O HLA-B27 negativo teve tendência à correlação com artrite de mãos e punhos (p=0,07). Houve correlação inversa significativa entre os valores do HLA e do teste de Schöber (p=0,02). CONCLUSÃO: Apesar do HLA-B27 ser negativo na maioria dos pacientes estudados, esteve significativamente associado ao sexo masculino e inversamente correlacionado ao teste de Schöber.
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Arthritis, Psoriatic/immunology , /analysis , Biomarkers/analysis , Cross-Sectional Studies , Socioeconomic FactorsABSTRACT
Las artropatías seronegativas o espondiloartropatías corresponden a un grupo de enfermedades que comparten características clínicas y genéticas, asociadas fuertemente con el complejo mayor de histocompatibilidad clase I HLA-B27. El rol patogénico del HLA-B27 es desconocido; se han propuesto múltiples teorías, entre las cuales cabe destacar tres: 1) péptido artritogénico, 2) cadenas pesadas aberrantes en la superficie celular y 3) estrés en el retículo endoplásmico rugoso. Es conocido que los linfocitos T CD4 tienen un rol primordial en esta patología. Se ha encontrado que en la mayoría de estas artropatías hay una gran producción de citoquinas del perfil Th1, sobre todo de TNF alfa, el que jugaría un rol crucial, pues se ha visto que con los fármacos anti TNF se produce una mejoría en la mayoría de estas patologías.
Seronegative arthropathies or spondyloarthropathy belong to a group of diseases that share clinical and genetic characteristics associated strongly with major histocompatibility complex class I HLA-B27. The pathogenic role of HLA-B27 is unknown, many theories have been proposed, among which we highlight three: 1) arthritogenic peptides, 2) aberrant heavy chains on the cell surface and 3) stress on the rough endoplasmic reticulum. It is known that CD4 T lymphocytes have a pivotal role in this pathology. A great production of Th1 profile cytokines have been found to exist in most of these arthropathies, especially TNF alpha., which may play a crucial role, since anti-TNF drugs have been known to produce an improvement in most of these pathologies.
Subject(s)
Humans , /immunology , Spondylarthropathies/immunology , Arthritis, Psoriatic/immunology , Arthritis, Reactive/immunology , Killer Cells, Natural/immunology , Tumor Necrosis Factor-alpha/immunology , /immunologyABSTRACT
The anti-cyclic citrullinated peptide (Anti-CCP) antibodies are actually the markers of highly specific recognize for rheumatoid arthritis (RA). Its presence in RA has been associated with higher disease clinical activity characterize by greater loss of function and development of erosive illness with important radiological damage. Furthermore, its production is an early process in RA development and because that, their presence is predictive for disease development. But in spite of the fact its high specificity, in the last years they also has been detected in other arthropathies diseases like psoriatic arthritis (PsA). Even if the prevalence of Anti-CCP in PsA reach values greater than expected for a disease different of AR, doesn`t reach statistical value, but its presence in this illness, like in AR, could might considerer a marker of disease severity, with development of aggressive clinic characteristics, polyarticular predominance, erosion presence and associated with shared epitope allele. The existing information don´t allow defining if this patience will develop more aggressive illness or existing concomitance of two joint diseases. More detail studies are necessary to defined that.
Subject(s)
Humans , Arthritis, Psoriatic/immunology , Arthritis, Rheumatoid/immunology , Citrulline/blood , Peptides, Cyclic/blood , Arthritis, Psoriatic/diagnosis , Arthritis, Rheumatoid/diagnosis , Autoantibodies/blood , Citrulline/immunology , Biomarkers , Peptides, Cyclic/immunologyABSTRACT
Cinqüenta e cinco soros de pacientes portadores de espondiloartropatias soronegativas, lúpus eritematoso sistêmico e artrite reumatóide foram selecionados para o estudo. Todos os soros mostravam fator reumatóide negativo pela prova de látex. A determinaçäo da interferência na fagocitose de gamaglobulina agregada por macrófagos de cobaia foi obtida por uma fórmula. A caracterizaçäo dos soros foi discriminada pela reaçäo daqueles que mostraram resultados mais expressivos na interferência sobre a fagocitose, facilitando ou inibindo-a. Os resultados, em valores absolutos e percentuais, mostraram a predominância do fenômeno da interferência na fagocitose, com valores significantes estatisticamente (p<0,05), quando comparado com soro normal. A análise comparativa entre as doenças estudadas na quantificaçäo da interferência do soro na fagocitose de imunocomplexo näo mostrou diferença significativa. A inibiçäo da fagocitose ocorreu com mais predominância no soro de pacientes com síndrome de Reiter e artrite psoriática; no soro de pacientes com síndrome de Reiter houve uma diferença estatisticamente significante na inibiçäo da fagocitose (p=0,0247). A caracterizaçäo da fraçäo sérica responsável pela interferência na fagocitose näo foi demonstrada. No estado atual dos conhecimentos, näo há uniformidade nas curvas de diluiçäo estudadas. É enfatizada a possibilidade de existência de mais de um elemento interferindo na fagocitose de imunocomplexos.